ArticleActa neurologica Scandinavica2020
Medication adherence/persistence among patients with active multiple sclerosis in Finland.
Article in Acta neurologica Scandinavica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.Journal of neurology · 2022Pooled it
- Adherence to asthma medication and asthma control in Finland.BMC pulmonary medicine · 2026Article
- Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment.Neurology and therapy · 2025Article
- Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.Journal of neurology · 2025Article
- Evaluation of the Efficacy, Safety, and Adherence to Oral Drug Therapy in Patients with Relapsing-Remitting Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2025Article
- Evolving Patterns of Initial RRMS Treatment in Finland (2013-2022): Insights From a Nationwide Multiple Sclerosis Register.Brain and behavior · 2025Article
- Real-world persistence of multiple sclerosis disease-modifying therapies.European journal of neurology · 2024Article
- Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.BMC neurology · 2024Observational
- Psychometric evaluation of the 5-item Medication Adherence Report Scale questionnaire in persons with multiple sclerosis.PloS one · 2024Article
- Treatment Courses of Patients Newly Diagnosed with Multiple Sclerosis in 2012-2018.Journal of clinical medicine · 2023Article
- Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Disease modifying therapies for multiple sclerosis: benefit and acceptability.British journal of neuroscience nursing · 2022Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.Journal of managed care & specialty pharmacy · 2021Article
- Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies.Journal of central nervous system disease · 2021Article
- Medication adherence/persistence among patients with active multiple sclerosis in Finland.Acta neurologica Scandinavica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
objectivesTo explore adherence, persistence, and treatment patterns in patients with multiple sclerosis (MS) in Finland treated with disease-modifying therapies (DMTs) for active MS in 2005-2018. MATERIALS AND
methodsThe study cohort was identified using the Drug Prescription Register of Social Insurance Institute, Finland. All patients had at least one prescription of glatiramer acetate (GA), beta-interferons, teriflunomide, or delayed-release dimethyl fumarate (DMF). Adherence was calculated using proportion of days covered (PDC) (cutoff ≥0.8). Time to non-persistence was calculated by the number of days on index DMT treatment before the first treatment gap (≥90 days) or switch and analyzed with time-to-event methodology.
resultsThe cohort included 7474 MS patients (72.2% female; mean age 38.9 years). Treatment switches were steady over 2005-2012, peaked in 2015. PDC means (standard deviations) were GA, 0.87 (0.17); beta-interferons, 0.88 (0.15); DMF, 0.89 (0.14); teriflunomide, 0.93 (0.10). Adherence frequencies were GA, 78.4%; beta-interferons, 81.3%; DMF, 86.9%; teriflunomide, 91.7%. Logistic regression showed that age group, DMT and the starting year, sex, and hospital district independently affected adherence. Patients receiving teriflunomide and DMF, males, and older patients were more likely to persist on treatment. There was no difference in persistence between patients prescribed teriflunomide and DMF, or between GA and beta-interferons.
conclusionsOral DMTs had greater adherence and persistence than injectable DMTs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.